Phase II Trial Insights on Molecular Glioblastoma with IDH Wildtype Lower Grade Features
Overview
This phase II trial explores treatment intensification using tighter radiotherapy margins combined with chemotherapy in molecular glioblastoma (molGBM) patients historically classified as lower grade IDH-wildtype gliomas. Preliminary analyses reveal heterogeneity within molGBM, with DNA methylation profiling correlating with overall survival, underscoring the need for refined risk stratification.
Background
Molecular glioblastoma (molGBM) represents IDH-wildtype gliomas lacking classic histological grade 4 features such as necrosis or microvascular proliferation and were previously classified as lower grade gliomas. These tumors often show minimal contrast enhancement on imaging and have distinct survival and treatment response profiles compared to histological GBM. Prior retrospective data suggested similar median survival between molGBM and histGBM, but with differences in progression-free survival and treatment intensity. Prospective data on optimal radiation volumes, imaging response, and molecular stratification remain limited, complicating evidence-based management.
Data Highlights
The ongoing single-center phase II trial enrolled 25 patients with molGBM (historical WHO grade 2/3 IDH-wildtype gliomas) treated with escalated radiotherapy doses (60 Gy to GTV, 50 Gy to CTV) and concurrent/adjuvant temozolomide. Radiation volumes were defined using FLAIR imaging with 1–2 cm margins respecting anatomical boundaries. DNA methylation profiling was performed on available tissue, requiring a methylation class score >0.9 for high-confidence classification. Survival analyses utilized Kaplan-Meier estimates, restricted mean survival time (RMST), and Cox proportional hazards models. Final accrual target is 38 evaluable patients.
Key Findings
molGBM patients treated with intensified radiotherapy and chemotherapy show potential for extended survival compared to historical controls receiving less intensive therapy.
DNA methylation-based epigenetic profiling reveals molecular heterogeneity within molGBM, correlating with overall survival outcomes.
Radiotherapy planning using tighter margins (1–2 cm expansions from GTV/FLAIR-defined tumor) is feasible and tailored to tumor imaging characteristics.
Preliminary survival data suggest that molGBM differs biologically and clinically from histological GBM despite overlapping median overall survival.
Concurrent and adjuvant temozolomide chemotherapy was incorporated, reflecting evolving standard-of-care approaches for molGBM.
Clinical Implications
These findings highlight the importance of molecular and epigenetic characterization in guiding treatment decisions for molGBM patients. Tailored radiotherapy volumes based on imaging and molecular features may optimize tumor control while minimizing toxicity. Incorporating chemotherapy alongside intensified radiotherapy appears feasible and may improve outcomes in this distinct patient population.
Conclusion
Prospective evaluation of molGBM with integrated molecular profiling and treatment intensification demonstrates the necessity for refined risk stratification to inform standard-of-care management. Ongoing accrual and final analyses will further clarify optimal therapeutic strategies.
References
WHO Classification of CNS Tumors 2021 -- Molecular Glioblastoma Definition
by Debra Nana Yeboa, Benjamin T. Whitfield, Ruitao Lin, Chinenye Lynette Ejezie, Todd A. Swanson, Thomas H. Beckham, Chenyang Wang, Brian De, Subha Perni, Martin C. Tom, Jing Li, Susan L. McGovern, Rebecca Harrison, Nazanin K. Majd, Vinay K. Puduvalli, Ashley E. Aaroe, Monica Loghin, Barbara J. O’Brien, Anuj D. Patel, Chirag B. Patel, Jeffrey S. Wefel, Ceylan Altintas Taslicay, Maria Gule-Monroe, Arnold C. Paulino, Mary Frances McAleer, David R. Grosshans, Amol J. Ghia, Wen Jiang, Caroline Chung, Moshe Maor, Cheng-Han Yang, Maria A. Gubbiotti, Carlos Kamiya-Matsuoka, Leomar Y. Ballester, Shiao-Pei Weathers, Jason T. Huse
